IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Edible Hepatitis B Vaccine Therapy in Healthy Participants Who Have Undergone Previous Vaccination
This study has been withdrawn prior to enrollment.
Sponsor:
Roswell Park Cancer Institute
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT01292421
First received: February 8, 2011
Last updated: January 29, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Hepatitis B antigen peptide (HBsAg) vaccine may help the body build an immune response and help prevent hepatitis B. PURPOSE: This clinical trial studies edible HBsAg vaccine therapy in healthy participants who have undergone previous vaccination.
| Condition | Intervention |
|---|---|
| Healthy, no Evidence of Disease | Biological: hepatitis B antigen peptide Other: placebo Other: immunoenzyme technique |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Prevention |
| Official Title: | Pilot Study Testing the Immunogenic Efficacy of an Edible Vaccine for Hepatitis B in Healthy Volunteers |
Resource links provided by NLM:
Further study details as provided by Roswell Park Cancer Institute:
Primary Outcome Measures:
- Maximum fold increase in anti-HBsAg titer levels relative to baseline levels [ Time Frame: Over 70 days ]
Secondary Outcome Measures:
- Absolute maximum response [ Time Frame: On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114 ]
- Area under the curve [ Time Frame: On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114 ]
- Proportion of two-fold responses in anti-HBsAg titer levels [ Time Frame: On days 0, 7, 14, 21, 28, 35, 42, 56 70, 84, 98, and 114 ]
| Enrollment: | 0 |
| Study Start Date: | February 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Arm I
Participants consume placebo HBV-EPV on days 0, 14, 28, and 56.
|
Other: placebo
Given orally (PO)
Other Name: PLCB
Other: immunoenzyme technique
Correlative studies
Other Name: immunoenzyme techniques
|
|
Experimental: Arm II
Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56.
|
Biological: hepatitis B antigen peptide
Given PO
Other Names:
Other: placebo
Given orally (PO)
Other Name: PLCB
Other: immunoenzyme technique
Correlative studies
Other Name: immunoenzyme techniques
|
|
Experimental: Arm III
Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14.
|
Biological: hepatitis B antigen peptide
Given PO
Other Names:
Other: placebo
Given orally (PO)
Other Name: PLCB
Other: immunoenzyme technique
Correlative studies
Other Name: immunoenzyme techniques
|
|
Experimental: Arm IV
Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56.
|
Biological: hepatitis B antigen peptide
Given PO
Other Names:
Other: immunoenzyme technique
Correlative studies
Other Name: immunoenzyme techniques
|
Detailed Description:
OBJECTIVES: I. To evaluate the safety, tolerability, and immunogenicity of orally delivered HBsAg that is formulated as an expressed protein in transgenic potato tubers (HBV-EPV) at different doses and schedules. OUTLINE: Patients are randomized to 1 of 4 treatment arms. ARM I: Participants consume placebo HBV-EPV on days 0, 14, 28, and 56. ARM II: Participants consume HBV-EPV expressing HBsAg on days 0 and 28 and placebo HBV-EPV on days 14 and 56. ARM III: Participants consume HBV-EPV expressing HBsAg on days 0, 28, and 56 and placebo HBV-EPV on day 14. ARM IV: Participants consume HBV-EPV expressing HBsAg on days 0, 14, 28, and 56. After completion of study treatment, patients are followed up at days 70, 84, 98, and 114.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- All Roswell Park Cancer Institute (RPCI) staff, faculty, and students, who are in good health
- Participants confirmation of history of primary immunization series with recombinant hepatitis B (HB) vaccine (last dose at least one year prior to screening anti-HBs level assessment)
- Current anti-HBs levels less than or equal to 115 mIU/mL
- Major organ functions within acceptable medical limits as determined in routine clinical laboratory screening tests
- Expected availability for the duration of the study period
- If female, then documentation that the subject is not pregnant by an acceptable laboratory test and that the subject is using an adequate birth control method to prevent pregnancy for at least 3 months following the last immunization in the study
- Human immunodeficiency virus (HIV) antibody negative
- Ability to provide written informed consent
- Supervisor approval
Exclusion Criteria:
- Known history of allergy or hypersensitivity to potato, potato components or potato products
- Known history of allergy to hepatitis B vaccine in any form or to components of hepatitis B vaccine
- Pregnancy or breast feeding
- Current anti-HBS levels greater than 115 mIU/mL
- Known immunodeficiency, cancer, or use of immunosuppressive medication including cancer chemotherapy and systemic steroids (excluding intermittent use of topical steroids)
- Participation in another investigational study within 30 days of enrollment in this study
- Known and currently active gastrointestinal disease including any of the following: peptic ulcer disease, gastroesophageal reflux, inflammatory bowel disease, diverticulitis, or pancreatitis
- Use of prescription medication or over the counter H2 blockers or proton pump inhibitors (PPIs) for any of the above diseases regularly and within 1 month of enrollment
- Diagnosis of insulin-dependent diabetes or multiple sclerosis
- Significant laboratory abnormality which suggests dysfunction of hematological, renal, or hepatic systems
- Known history of hepatitis B infection in the past
- Temporary exclusion for mild upper respiratory illness, gastrointestinal illness, or other febrile episode that is expected and documented to resolve
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01292421
Please refer to this study by its ClinicalTrials.gov identifier: NCT01292421
Sponsors and Collaborators
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Renuka Iyer | Roswell Park Cancer Institute |
More Information
| Responsible Party: | Roswell Park Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT01292421 History of Changes |
| Other Study ID Numbers: |
I 124207 NCI-2011-00064 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) |
| Study First Received: | February 8, 2011 |
| Last Updated: | January 29, 2013 |
Additional relevant MeSH terms:
|
Hepatitis B Hepadnaviridae Infections DNA Virus Infections Virus Diseases |
Hepatitis, Viral, Human Hepatitis Liver Diseases Digestive System Diseases |
ClinicalTrials.gov processed this record on August 18, 2017